LEIDEN, THE NETHERLANDS – May 13, 2014 – Prosensa Holding N.V. (NASDAQ: RNA) today announced that the Company will host a conference call and live audio webcast on Tuesday, May 20, 2014 8:00 a.m. US Eastern Time (2:00 p.m. Central European Time) to report its first quarter financial results and provide a corporate update.
In order to participate in the conference call, please dial 1-877-407-9170 (US Domestic toll-free). International dial-in numbers and an audio webcast can be accessed under "Events & Presentations" through the Investors & Media section of the Prosensa corporate website at www.prosensa.com.
About Prosensa Holding N.V.
Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Its primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy (DMD), myotonic dystrophy and Huntington’s disease.
Prosensa’s current portfolio includes six compounds for the treatment of DMD, all of which have received orphan drug status in the United States and the European Union. The compounds use an innovative technique called exon-skipping to provide a personalized medicine approach to treat different populations of DMD patients. www.prosensa.com Issued for and on behalf of Prosensa Holding N.V. by Instinctif Partners.
For more information please contact:
Prosensa Holding N.V.
Celia Economides, Director IR & Corporate Communications
Phone: +1 917 941 9059
Email: c.economides@prosensa.nl
Help employers find you! Check out all the jobs and post your resume.
